Subsequent corroborative studies by Hughes et al. (19) have demonstrated that AhR antagonism suppresses multiple myeloma cell viability, alters immune surface markers, and sensitizes multiple myeloma to NK cell cytotoxicity. Here, AHR is linked to plasma cell myeloma.